article thumbnail

Scientists reveal new method that could reduce waste from drug manufacturing

PharmaTimes

The new method could help to prevent severe side effects caused by enantiomer drugs

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

But along with strong efficacy come some considerable risks and costs: cytokine release syndrome (CRS), where a patient’s immune system becomes dangerously over-stimulated, and neurotoxicity are potential side effects that need to be managed. Side effects and cost implications.

article thumbnail

New UK intracellular drug delivery centre to support RNA development

Pharmaceutical Technology

The funding is being provided under the agency’s Transforming Medicines Manufacturing programme. It will also help predict any potential side effects of these medicines. This could prove to be beneficial for patients and the health system by providing increased access to advanced, cost-effective drugs.

article thumbnail

AI-Designed Custom Knee Implants

Medgadget

The goal is that medical interventions are highly tuned to the patient they are directed at, in the hope that tailoring therapeutic interventions will lead to better patient outcomes and reduced instances of side-effects. They then used an electron beam powder bed fusion to manufacture their designs.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

However, disease heterogeneity has limited the field’s understanding of lupus, and the regulatory requirements for manufacturing and developing cell therapies have proven to be a hurdle. “[The] There are only a handful of institutions that are able to make these cells, and getting regulatory support for this is also a challenge, he adds.

article thumbnail

“Game-changing” obesity drug over-promising?

World of DTC Marketing

“Obesity is multifactorial, meaning many factors are involved and go from genetics, lifestyle, mental health issues (such as trauma) to medication side effects,” says Dr. Many factors contribute to obesity. Nearly 3% of the overall U.S. The reasons are complex. Many factors contribute to obesity.

Insurance 271